Top Ten Articles 2020

Top Ten Articles on Atopic Dermatitis 2020: Chosen by the International Eczema Council. 

  1. Simpson, Eric L et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet (London, England) vol. 396,10246 (2020): 255-266. 
  2. Chalmers, Joanne R et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet (London, England) vol. 395,10228 (2020): 962-972.
  3. Simpson, E L et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. The British Journal of Dermatology vol. 183,2 (2020): 242-255.
  4. Kabashima, Kenji et al. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. The New England Journal of Medicine vol. 383,2 (2020): 141-150.
  5. Skjerven, Håvard Ove et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet (London, England) vol. 395,10228 (2020): 951-961.
  6. He, Helen et al. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. The Journal of Allergy and Clinical Immunology vol. 145,6 (2020): 1615-1628.
  7. Wollenberg, A et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). The British Journal of Dermatology vol. 184,3 (2021): 437-449.
  8. Guttman-Yassky, Emma et al. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.  JAMA Dermatology vol. 156,4 (2020): 411-420.
  9. He, Helen et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. The Journal of Allergy and Clinical Immunology vol. 147,1 (2021): 199-212. 
  10. Paller, Amy S et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. Journal of the American Academy of Dermatology vol. 83,2 (2020): 375-381. 

Other Important Articles in AD: Chosen by the International Eczema Council.

  1. Rojahn, Thomas B et al. Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type-specific immune regulation in atopic dermatitis. The Journal of Allergy and Clinical Immunology vol. 146,5 (2020): 1056-1069.
  2. Simpson, Eric et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. Journal of the American Academy of Dermatology vol. 83,3 (2020): 839-846. 
  3. He, Helen et al. Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers. Frontiers in immunology vol. 11 1768. 6 Aug. 2020.
  4. Silverberg, J I et al. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study. The British Journal of Dermatology, 10.1111/bjd.19457. 5 Aug. 2020.
  5. Lauffer, Felix et al. Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins. Allergy vol. 76,4 (2021): 1158-1172.
  6. Nakagawa, Hidemi et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. Journal of the American Academy of Dermatology vol. 82,4 (2020): 823-831.
  7. Pascal, C et al. Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. Journal of the European Academy of Dermatology and Venereology : JEADV vol. 34,10 (2020): 2339-2345.
  8. Ungar, Benjamin et al. A Preliminary 18F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis. The Journal of Allergy and Clinical Immunology. In practice vol. 8,10 (2020): 3500-3506. 
  9. Möbus, Lena et al. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. The Journal of Allergy and Clinical Immunology vol. 147,1 (2021): 213-223. 
  10. Suh, Timothy P et al. Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children. Journal of the American Academy of Dermatology vol. 82,5 (2020): 1187-1194. 

Click on the ‘Abstract’ link for above-referenced articles on PubMed, along with copyright information.